Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + cisplatin + tegafur + uracil + leucovorin
- Development stage
- Unknown
- Lead developer
- Taipei Veterans General Hospital
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This combination chemotherapy regimen, often referred to as the DCU regimen, consists of docetaxel, cisplatin, and oral tegafur/uracil (UFUR) supplemented with leucovorin. It was evaluated in a Phase II clinical trial led by Taipei Veterans General Hospital for the treatment of advanced oral tongue squamous cell carcinoma (OTSCC). The strategy employs induction chemotherapy to shrink tumors before tongue conservation surgery, followed by risk-adapted postoperative adjuvant therapy. Docetaxel acts as a microtubule stabilizer, cisplatin as a DNA-damaging agent, and tegafur/uracil as an oral fluoropyrimidine that inhibits thymidylate synthase. This multi-modal cytotoxic approach targets rapidly dividing cancer cells to improve organ preservation and survival outcomes in patients with cT2-4 N0-2 M0 stage disease.
- Brand names
- UFUR
- Other names
- DCU regimenInduction chemotherapy with DCU regimen
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)DNA
Beyond the preview
Go deeper on docetaxel + cisplatin + tegafur + uracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + cisplatin + tegafur + uracil + leucovorin.